Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting

The operating financial results of the Company’s R&D segment for the three and six months ended June 30, 2025 and 2024 are as follows (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Revenue	$	1,497	$	—	$	2,355	$	—
Less: Significant segment expenses
Personnel-related expenses	5,593		4,874		10,779		9,554
Clinical and preclinical expenses	4,710		4,320		9,189		8,694
Facilities-related and overhead	2,022		1,809		3,998		3,718
Professional and consulting fees	1,584		1,294		3,186		2,815
Corporate expenses	456		255		1,037		496
Travel and entertainment	160		110		294		260
Plus: Other segment income	441		86		1,108		509
Segment net loss	$	(12,587)	$	(12,576)	$	(25,020)	$	(25,028)